X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
REN001 (mavodelpar) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of primary mitochondrial myopathies (PMM).
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPAR delta agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
The net proceeds will be used to fund the development of company's lead product, REN001 (mavodelpar), a potent and selective agonist of the peroxisome proliferator-activated receptor delta, in adult patients with PMM due to mitochondrial DNA, or mtDNA, defects.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
